A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in adult participants with Moderate to Severe Atopic Dermatitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505414-15-00

Acronym

219538

Enrollment

Registered

2024-03-04

Start date

2024-04-10

Completion date

2025-04-08

Last updated

2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic, Dermatitis

Brief summary

Percent Change From Baseline in the Eczema Area and Severity Index (EASI) to Week 16.

Interventions

DRUGLocally Sourced 0.9% Sodium Chloride

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent Change From Baseline in the Eczema Area and Severity Index (EASI) to Week 16.	—

Countries

Bulgaria, Czechia, France, Germany, Greece, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026